Clene Inc. Financing Cash Flow
Clene Inc. (CLNN) reported Financing Cash Flow of $11.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Clene Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $6.33M, a 196.72% increase year-over-year.
- Clene Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.23M, a 95.81% increase year-over-year.
- Clene Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.07M, a 18.12% decline year-over-year.
- Clene Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.64M.
- Clene Inc. net cash provided by (used in) financing activities for fiscal 2025 was $11.52M.
- Clene Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$1.53M, a 103.63% decline from fiscal 2023.
- Clene Inc. net cash provided by (used in) financing activities for fiscal 2023 was $42.16M, a 144.44% increase from fiscal 2022.
- Clene Inc. net cash provided by (used in) financing activities for fiscal 2022 was $17.25M, a 36.38% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $11.56M 10-Q · filed 2026-08-14 | $13.63M derived: sum of 3 quarters · filed 2026-08-14 | $18.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.23M 10-Q · filed 2026-05-14 | $7.30M derived: sum of 2 quarters · filed 2026-05-14 | $11.95M derived: sum of 3 quarters · filed 2026-05-14 | $14.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.71M derived: sum of 2 quarters · filed 2026-03-17 | $8.85M derived: sum of 3 quarters · filed 2026-08-14 | $11.52M 10-K · filed 2026-03-17 |
| 2025-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.78M derived: sum of 2 quarters · filed 2026-08-14 | $9.45M 10-Q · filed 2025-11-13 | $11.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.81M 10-Q · filed 2026-08-14 | $7.33M derived: sum of 3 quarters · filed 2026-08-14 | $3.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.67M 10-Q · filed 2026-05-14 | $5.20M derived: sum of 2 quarters · filed 2026-05-14 | $1.14M derived: sum of 3 quarters · filed 2026-05-14 | $1.16M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.54M derived: sum of 2 quarters · filed 2026-03-17 | -$1.51M derived: sum of 3 quarters · filed 2026-03-17 | -$1.53M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.04M derived: sum of 2 quarters · filed 2025-11-13 | -$4.06M 10-Q · filed 2025-11-13 | -$4.08M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $9.00K 10-Q · filed 2025-08-14 | -$9.00K derived: sum of 3 quarters · filed 2025-08-14 | -$246.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$19.00K 10-Q · filed 2025-05-07 | -$37.00K derived: sum of 2 quarters · filed 2025-05-07 | -$274.00K derived: sum of 3 quarters · filed 2025-05-07 | $37.56M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$255.00K derived: sum of 2 quarters · filed 2025-03-24 | $37.58M derived: sum of 3 quarters · filed 2025-03-24 | $42.16M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $37.59M derived: sum of 2 quarters · filed 2024-11-13 | $42.18M 10-Q · filed 2024-11-13 | $58.55M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $37.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $42.42M 10-Q · filed 2024-08-07 | $58.79M derived: sum of 3 quarters · filed 2024-08-07 | $58.88M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $4.59M 10-Q · filed 2024-05-08 | $20.96M derived: sum of 2 quarters · filed 2024-05-08 | $21.05M derived: sum of 3 quarters · filed 2024-05-08 | $21.60M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $16.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $16.47M derived: sum of 2 quarters · filed 2024-03-13 | $17.01M derived: sum of 3 quarters · filed 2024-03-13 | $17.25M 10-K · filed 2024-03-13 |
| 2022-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $640.00K derived: sum of 2 quarters · filed 2023-11-07 | $875.00K 10-Q · filed 2023-11-07 | $857.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $783.00K 10-Q · filed 2023-08-14 | $765.00K derived: sum of 3 quarters · filed 2023-08-14 | $6.00M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $235.00K 10-Q · filed 2023-05-12 | $217.00K derived: sum of 2 quarters · filed 2023-05-12 | $5.45M derived: sum of 3 quarters · filed 2023-05-12 | $29.24M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $5.21M derived: sum of 2 quarters · filed 2023-03-13 | $29.01M derived: sum of 3 quarters · filed 2023-03-13 | $27.11M 10-K · filed 2023-03-13 |
| 2021-09-30 | $5.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $29.03M derived: sum of 2 quarters · filed 2022-11-07 | $27.13M 10-Q · filed 2022-11-07 | $55.30M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $23.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $21.90M 10-Q · filed 2022-08-15 | $50.07M derived: sum of 3 quarters · filed 2022-08-15 | $87.76M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$1.90M 10-Q · filed 2022-05-09 | $26.27M derived: sum of 2 quarters · filed 2022-05-09 | $63.97M derived: sum of 3 quarters · filed 2022-05-09 | $66.09M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $28.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $65.87M derived: sum of 2 quarters · filed 2022-03-11 | $67.99M derived: sum of 3 quarters · filed 2022-03-11 | $69.53M 10-K · filed 2022-03-11 |
| 2020-09-30 | $37.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $39.82M derived: sum of 2 quarters · filed 2021-11-08 | $41.36M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.67M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.55M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $5.50M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |